# hims & hers account plan

> Hims & Hers Health (NYSE: HIMS) runs a consumer telehealth platform with FY2025 revenue of $2,347.6 million and 2,442 employees.

## At a glance

Hims & Hers Health, Inc. (NYSE: HIMS) launched in 2017 and runs a consumer-first telehealth platform covering sexual health, hair loss, hormone health, weight loss, dermatology and mental health, plus laboratory testing. Customers buy through websites and mobile apps and are connected to licensed providers, with prescriptions fulfilled by licensed pharmacies, many of them company-owned. It operates in the United States, the United Kingdom, parts of the European Union and Canada, and added Australia and Japan with Eucalyptus in June 2026. FY2025 revenue was $2,347.6 million, up 59%, with net income of $128.4 million and 2,442 employees at December 31, 2025. The company is independent and listed, and Andrew Dudum is Co-Founder, Chairman and CEO.

## Business units

- **United States** ($2,213.6 million of FY2025 revenue (United States Revenue)): Sales by US entities, up 53% in FY2025, driven by personalized offerings (over 70% of United States Revenue) and the Hers brand (nearly 40%). In the quarter ended September 30, 2026, United States Revenue was $657.1 million, up 21%.
- **Rest of the World** ($134.0 million of FY2025 revenue (Rest of the World Revenue)): Sales in the United Kingdom, parts of the European Union and Canada after the Zava and Medici acquisitions; in the quarter ended September 30, 2026 it reached $233.3 million, up 321%, with Eucalyptus closed in June 2026.
- **Wholesale** ($36.2 million of FY2025 revenue): Non-prescription product sales to retailers and consignment sales to third-party platforms, down 6% in FY2025. The company does not anticipate launching new material wholesale partnerships.

## Strategic priorities

- **Win metabolic health**: Management's first commitment is to win metabolic health in the U.S. and around the world, through a Novo Nordisk collaboration and a Lilly agreement for Zepbound and Foundayo, with multi-month subscriptions planned. Since March 2026 the US weight loss offering centres on branded GLP-1 medications, with compounded GLP-1s offered on a limited scale.
- **Lead in major international markets**: The company directs more investment to the U.K., Germany and Australia and is consolidating brands under Hims & Hers. International revenue is expected to be at least $650 million in 2026, and the CEO says it is on track to eclipse a $1 billion revenue run rate in 2027.
- **AI-native care platform**: The AI-native experience reached 70% of weight loss subscribers at the end of Q3 2026, with nearly 100% expected before year-end. Customers using it send 4x as many messages, and the company says it is aimed at engagement, retention and lower cost to serve.
- **Category expansion**: Injectable and oral testosterone launched as the first controlled substances, and a peptides offering (Sermorelin, Glutathione, NAD+) is planned for later in November 2026. BPC-157 and TB-500 depend on regulatory clarity. The 10-K names sleep disorders, post-traumatic stress disorder, fertility, diabetes, cholesterol and hypertension as future specialties.
- **Internal fulfillment**: The company wants a significant majority of pharmaceutical and over-the-counter orders fulfilled internally, through two 503A pharmacies, a 503B outsourcing facility, a peptide facility and a lab facility. Facility expansion is expected to continue for at least the next 12 months.
- **2030 ambitions**: On the Q2 2026 call the CFO reiterated 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

## Latest results

In the quarter ended September 30, 2026, revenue was $890.4 million, up 49% from $599.0 million, with a net loss of $33.0 million and Adjusted EBITDA of $82,388 thousand (9% margin). Gross margin fell to 57% from 74%, mainly from weight loss offerings with shorter shipping cadences, international growth and acquisitions. Subscribers were 2,788 thousand, up 13% year on year but down 100,000 sequentially after deliberately measured domestic weight loss marketing. Guidance for Q4 2026 is revenue of $875 million to $895 million; for 2026, revenue of $3.13 billion to $3.15 billion and adjusted EBITDA of $257 million to $277 million (reduced). Liquidity was $712.2 million at September 30, 2026.

## Investments and deals

- **Eucalyptus acquisition**: Closed in June 2026 for a purchase price for accounting purposes of $968.5 million, including $225.0 million upfront and $683.9 million of deferred payments in six quarterly installments.
- **YourBio Health merger**: Completed in January 2026 to bring in capillary whole blood sampling technology, with a purchase price for accounting purposes of $153.0 million.
- **Zava and Medici**: Zava was acquired in July 2025 (EUR 219.2 million, or $258.0 million) and Medici in Canada in November 2025 (CAD 39.1 million, or $27.8 million).
- **Financing**: $1.0 billion of 0% convertible senior notes due 2030 (May 2025), $402.5 million due 2032 (May 2026), and a receivables purchase agreement with a $400.0 million uncommitted limit (July 2026).
- **Technology and AI hiring**: The CTO and CFO described Q3 2026 as the largest hiring quarter in the history of the engineering organization, and an AI R&D lab in Menlo Park was planned on the Q2 2026 call.

## Challenges and risks

- **Compounded GLP-1 regulation**: The FDA resolved the semaglutide shortage on February 21, 2025, and in February 2026 stated it intends to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, naming the company. HHS said it referred the company to the DOJ for investigation, and the 10-K says it is unclear what actions may follow.
- **Litigation**: Novo Nordisk filed a patent infringement lawsuit on February 9, 2026, and a securities class action is pending. On July 29, 2026 the FTC and others filed a complaint over subscription and cancellation practices, for which the company accrued approximately $60 million and has filed a motion to dismiss.
- **Margin pressure**: Gross margin was 57% in the third quarter of 2026 against 74%, from branded weight loss, shorter shipping cadences and international mix; management expects the decline to start to moderate.
- **Subscriber volatility**: Subscribers declined by 100,000 sequentially in Q3 2026, and the company warns of another quarter of headwinds from moderated US weight loss marketing and international brand consolidation.
- **Dependence on affiliated medical groups**: US clinical services are provided by Affiliated Medical Groups the company does not own, and the 10-K flags the risk that a regulator asserts corporate practice of medicine or fee-splitting violations.

## What leadership says

> "Our conviction is simple in healthcare, whoever owns the customer relationship wins." — Andrew Dudum, Co-Founder, Chairman and CEO, Third Quarter 2026 Earnings Call, November 9, 2026

> "the choice trades near-term subscriber growth for what we believe is a stronger long-term position." — Yemi Okupe, Chief Financial Officer, Third Quarter 2026 Earnings Call, November 9, 2026

> "We are making AI load-bearing, not decorative." — Mohamed ElShenawy, Chief Technology Officer, Second Quarter 2026 Earnings Call, August 10, 2026


## Where a supplier can help

- **AI-native care and support tooling**: The AI-native experience (70% of weight loss subscribers) and the stated aim to reduce reliance on agentic AI customer support vendors point to demand for clinical AI, evaluation and audit tooling, but also to a build-over-buy stance.
- **Fulfillment and compounding infrastructure**: The internal fulfillment priority and continued facility expansion over the next 12 months create needs for pharmacy automation, quality, cold-chain and laboratory supplier relationships.
- **International expansion services**: With brand consolidation in the U.K., Germany and Australia and at least $650 million of expected 2026 international revenue, local compliance, payments, localisation and marketing partners could be relevant.
- **Regulatory and legal support**: The FDA statement, the HHS referral, the Novo Nordisk and FTC matters make regulatory counsel, compliance monitoring and subscription-practice audit capabilities relevant.
- **Cost-of-capital and working capital tools**: The receivables purchase agreement, convertible notes and a working capital deficit of $114.8 million suggest interest in receivables financing and treasury solutions.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Hims & Hers Health, Inc. Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000022/hims-20251231.htm)

Annual report · 2026-02-23

- Hims & Hers Health, Inc. (NYSE: HIMS) launched in 2017 and runs a consumer-first telehealth platform covering sexual health, hair loss, hormone health, weight loss, dermatology and mental health, plus comprehensive laboratory testing; it conducts business through one operating segment.
- FY2025 revenue was $2,347.6 million, up 59% from $1,476.5 million in 2024; United States Revenue was $2,213.6 million and Rest of the World Revenue $134.0 million.
- Net income was $128.4 million and Adjusted EBITDA $318.0 million (14% margin); gross margin fell to 74% from 79% because of weight loss offerings with shorter shipping cadences and higher fulfillment costs.
- Subscribers grew 13% to approximately 2,511,000 at December 31, 2025; Monthly Revenue per Average Subscriber rose 28% to $83. Personalized offerings were over 70% of United States Revenue and the Hers brand nearly 40%.
- Strategy: more customers, more per customer, new specialties (testosterone, menopause, perimenopause and lab testing launched in 2025), more internal fulfillment (two 503A pharmacies, a 503B outsourcing facility, a peptide facility and a lab facility), and international expansion (Zava in July 2025, Medici in November 2025, a definitive agreement for Eucalyptus of up to $1.15 billion in February 2026).
- Financing: $1.0 billion of 0% convertible senior notes due 2030 issued in May 2025 and a $175.0 million revolving credit facility; principal sources of liquidity were $928.8 million at December 31, 2025.
- Regulatory and legal exposure is stated at length: in February 2026 the FDA issued a statement on GLP-1 active pharmaceutical ingredients for compounded drugs and named the company; HHS said it referred the company to the DOJ; Novo Nordisk filed a patent lawsuit on February 9, 2026; a securities class action is pending.
- Headcount: 2,442 employees and 1,586 medical providers through the Affiliated Medical Groups at December 31, 2025.

### [Hims & Hers Health, Inc. Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000246/hims-20260930.htm)

Interim report · 2026-11-09

- Q3 2026 (three months ended September 30, 2026): revenue $890.4 million, up 49% from $599.0 million; nine-month revenue $2,251.7 million, up 30%.
- United States Revenue was $657.1 million (up 21%) and Rest of the World Revenue $233.3 million (up 321%), helped by Eucalyptus, which closed in June 2026.
- Net loss was $33.0 million for the quarter and $211.4 million for nine months; Adjusted EBITDA was $82,388 thousand (9% margin) against $78,365 thousand (13%).
- Gross margin fell to 57% from 74%, mainly because of weight loss offerings with shorter shipping cadences and higher fulfillment costs, international growth and recent acquisitions.
- Subscribers were 2,788 thousand at September 30, 2026, up 13%; Monthly Revenue per Average Subscriber was $105 against $81.
- In March 2026 the company shifted its United States weight loss offering to branded GLP-1 medications and offers compounded GLP-1s on a limited scale; it launched a weight loss membership program at the end of March 2026.
- Legal: on July 29, 2026 the FTC and others filed a complaint over subscription and cancellation practices; the company recorded a legal contingency accrual of approximately $60 million and filed a motion to dismiss on October 22, 2026.
- Liquidity was $712.2 million at September 30, 2026; $402.5 million of 0% convertible senior notes due 2032 were issued in May 2026.

### [Third Quarter 2026 Earnings Call (company transcript)](https://s27.q4cdn.com/787306631/files/doc_financials/2026/q3/2026_Q3_Earnings_Transcript-docx.pdf)

Executive talk · Andrew Dudum, Co-Founder, Chairman and CEO · 2026-11-09

- Andrew Dudum frames the strategy as "in healthcare, whoever owns the customer relationship wins", built on owned brands, a platform, more than 1 million square feet of pharmacy, lab and compounding infrastructure, and AI.
- Three commitments: win metabolic health in the U.S. and around the world, lead the major markets globally, and lead category expansion.
- Q3 2026 revenue grew 49% to $890 million; subscribers grew 13% to 2.8 million but declined by 100,000 sequentially because of deliberately measured domestic weight loss marketing and international brand migrations.
- Weight loss: a Novo collaboration (Wegovy pen and pill, CagriSema planned) plus a new Lilly agreement for Zepbound and Foundayo; multi-month subscriptions planned before the new year.
- International: revenue of $233 million, including approximately $135 million from Eucalyptus; 2026 international revenue now expected to be at least $650 million, and Dudum says international is on track to eclipse a $1 billion revenue run rate in 2027.
- AI-native experience reached 70% of weight loss subscribers at quarter end, with customers sending 4x as many messages; record engineering hiring quarter.
- Guidance: Q4 revenue $875 million to $895 million; 2026 revenue $3.13 billion to $3.15 billion; 2026 adjusted EBITDA reduced to $257 million to $277 million.
- New categories: injectable and oral testosterone launched; a peptides offering (Sermorelin, Glutathione, NAD+) planned later in November; BPC-157 and TB-500 await regulatory clarity.

### [Second Quarter 2026 Earnings Call (Motley Fool transcript)](https://www.fool.com/earnings/call-transcripts/2026/08/17/hims-hims-q2-2026-earnings-call-transcript/)

Executive talk · Andrew Dudum, Co-Founder and CEO · 2026-08-10

- Q2 2026 call (August 10, 2026): revenue grew nearly 40% to more than $753 million; the company added 300,000 net new subscribers to reach nearly 3 million.
- U.S. revenue was $622 million, up 16%, as the March 2026 pivot to branded weight loss products (Novo Nordisk) re-accelerated growth; the Wegovy pill launch was called "staggering".
- International revenue increased over 17-fold to $131 million; Eucalyptus closed in June and contributed approximately $40 million.
- Adjusted EBITDA was $60 million (8% margin); gross margin 64%; GAAP net loss $86 million after approximately $81 million of non-recurring costs including FTC-related legal accruals.
- AI-native experience for Hers weight loss customers: 3x as many messages, AI answering 80% of questions, nonclinical support tasks cut by nearly 50%; an AI R&D lab planned in Menlo Park.
- Guidance: Q3 revenue $880 million to $900 million; 2026 revenue $3.1 billion to $3.3 billion and adjusted EBITDA $275 million to $325 million; international at least $600 million.
- 2030 ambitions reiterated: at least $6.5 billion of revenue and $1.3 billion of adjusted EBITDA.
- Financing: a $400 million receivables facility and a convertible offering of over $400 million; more than $840 million of cash and short-term investments after the Eucalyptus upfront payment.

## Questions about hims & hers

### What does Hims & Hers Health do?

It runs a consumer-first telehealth platform that connects customers to licensed providers for conditions such as sexual health, hair loss, hormone health, weight loss, dermatology and mental health, with prescriptions fulfilled by licensed pharmacies. It also sells non-prescription health and wellness products.

### How large is Hims & Hers Health?

FY2025 revenue was $2,347.6 million, up 59%, with net income of $128.4 million. It had 2,442 employees and approximately 2,511,000 Subscribers at December 31, 2025.

### What is Hims & Hers Health's strategy?

Management's three commitments are to win metabolic health, lead the major markets globally and lead category expansion, supported by an AI-native platform and internal pharmacy and lab infrastructure.

### Who leads Hims & Hers Health?

Andrew Dudum is Co-Founder, Chairman and CEO. Yemi Okupe is Chief Financial Officer and Mohamed ElShenawy is Chief Technology Officer.

### What is the regulatory position on compounded GLP-1s?

The company's filings state that the FDA, in February 2026, said it intends to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs and named the company, and that HHS referred it to the DOJ. Since March 2026 its US weight loss offering centres on branded GLP-1 medications.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)_
